The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02813135
Recruitment Status : Recruiting
First Posted : June 24, 2016
Last Update Posted : May 30, 2023
Sponsor:
Collaborator:
National Cancer Institute, France
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This proof-of-concept platform trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe (Geoerger 2017; Geoerger 2019).

The aims of the trial are:

  1. To determine the recommended phase II dose (RP2D) of a specific anticancer agent and/or a relevant combination in a pediatric population, to document its tolerability and
  2. To explore first signals of activity in a molecularly enriched study population.

Condition or disease Intervention/treatment Phase
Pediatric Cancer Drug: Ribociclib Drug: Topotecan Drug: Temozolomide Drug: Everolimus Drug: Adavosertib Drug: Carboplatin Drug: Olaparib Drug: Irinotecan Drug: Vistusertib Drug: Nivolumab Drug: Cyclophosphamide Drug: Selumetinib Drug: Enasidenib Drug: Lirilumab Drug: Fadraciclib Drug: Cytarabine Drug: Dexamethasone Drug: Ceralasertib Drug: Futibatinib Drug: Capmatinib Phase 1 Phase 2

Detailed Description:

The first molecular profiling protocols have been launched in Europe (MOSCATO-01 (Geoerger 2014), MAPPYACTS, INFORM, iTHER, SM-PAEDS, etc.) determining multiple actionable alterations in pediatric recurrent cancers. Increasingly, stratified approaches are being implemented to enrich clinical trials of molecularly targeted agents and possibly improve outcomes in specific populations i.e. a molecularly enriched/predictive biomarker-driven approach. The diversity and heterogeneity of the detected molecular alterations and the low number of pediatric patients mandate an adapted, innovative trial design for the attributed treatment options in order to satisfy the current unmet medical need.

This basket trial is designed to cover the targeting of several survival pathways in oncogenesis that are currently not adequately employed for pediatric patients in Europe.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 460 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Actual Study Start Date : August 3, 2016
Estimated Primary Completion Date : August 2027
Estimated Study Completion Date : August 2027
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A. Ribociclib + Topotecan and Temozolomide
Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
 Drug: Ribociclib
Other Names:
  • Kisqali
  • LEE011

Drug: Topotecan
Other Name: Hycamtin

Drug: Temozolomide
Other Name: Temodar
Experimental: Arm B. Ribociclib + Everolimus
Ribociclib capsules or oral solution orally QD for 21 days of each 28 day cycle; Everolimus orodispersible tablets orally QD for 28 days.
 Drug: Ribociclib
Other Names:
  • Kisqali
  • LEE011

Drug: Everolimus
Other Name: Afinitor
Experimental: ARM C. Adavosertib + Carboplatin
Adavosertib capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
 Drug: Adavosertib
Other Name: AZD1775

Drug: Carboplatin
Other Name: Paraplatin
Experimental: Arm D. Olaparib + Irinotecan
Olaparib tablets orally BID on Day 1-10 of a 21 day cycle Irinotecan iv QD on Day 4-8 of a 21 day cycle.
 Drug: Olaparib
Other Name: Lynparza

Drug: Irinotecan
Other Names:
  • Camptosar
  • CPT-11
Experimental: Arm E. Vistusertib single agent
Vistusertib tablets orally BID 2 days on/5 days off per week of a 28 day cycle.
 Drug: Vistusertib
Other Name: AZD2014
Experimental: Arm F. Vistusertib + Topotecan and Temozolomide
Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Vistusertib tablets orally BID 3 days on/4 days off per week of a 28 day cycle.
 Drug: Topotecan
Other Name: Hycamtin

Drug: Temozolomide
Other Name: Temodar

Drug: Vistusertib
Other Name: AZD2014
Experimental: Arm G. Nivolumab + Cyclophosphamide +/- Radiotherapy
Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Cyclophosphamide tablets or oral solution orally BID, 1 week on/1 week off; Palliative irradiation/radiofrequency/cryotherapy starting 2 weeks after the first nivolumab injection.
 Drug: Nivolumab
Other Name: Opdivo

Drug: Cyclophosphamide
Other Name: Cytoxan
Experimental: Arm H. Selumetinib + Vistusertib
Selumetinib capsules twice daily on a continous administration. Vistusertib orally twice daily on an intermittent schedule : 2 days on / 5 days off per week of a 28 day cycle.
 Drug: Vistusertib
Other Name: AZD2014

Drug: Selumetinib
Other Name: Koselugo
Experimental: Arm I. Enasidenib
Enasidenib tablets or sprinkle solution orally on a continuous dosing once daily (QD) per 28 day cycle.
 Drug: Enasidenib
Other Name: Idhifa
Experimental: Arm J. Lirilumab + Nivolumab
Nivolumab iv QD on Day 1 and 15 of a 28 day cycle; Lirilumab iv QD on Day 1 of a 28 day cycle
 Drug: Nivolumab
Other Name: Opdivo

Drug: Lirilumab
Other Name: BMS-986015
Experimental: Arm K. Fadraciclib (CYC065) + Temozolomide
Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Temozolomide capsules orally QD on Day 1-5 of a 28 day cycle
 Drug: Temozolomide
Other Name: Temodar

Drug: Fadraciclib
Other Name: CYC065
Experimental: Arm L. Fadraciclib (CYC065) + Cytarabine
Fadraciclib iv QD on Day 1 (+/- 15) of a 28 day cycle Cytarabine iv or sc on Day 2-5 and Day 8-11 of a 28 day cycle
 Drug: Fadraciclib
Other Name: CYC065

Drug: Cytarabine
Other Names:
  • Arabinosylcytosine
  • Cytosar-U
Experimental: Arm M. Ribociclib + Everolimus +/- Dexamethasone

Ribociclib capsules or tablets orally QD on Day 1-21 of a 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.

For patients with leukemia and lymphoma:

Dexamethasone orally or iv on Day 1-7 of each 28 day cycle. For patients with ALL, AML and Non-Hodgkin Lymphoma (NHL), Intrathecal chemotherapy will be administered additionally as per standard practice depending on CNS status.

 Drug: Ribociclib
Other Names:
  • Kisqali
  • LEE011

Drug: Everolimus
Other Name: Afinitor

Drug: Dexamethasone
Other Names:
  • Decadron
  • Dexasone
  • Diodex
  • Hexadrol
  • Maxidex
Experimental: Arm N. Ceralasertib (AZD6738) + Olaparib
Olaparib tablets orally BID per 28 days Ceralasertib tablets QD or BID per 28 day cycle
 Drug: Olaparib
Other Name: Lynparza

Drug: Ceralasertib
Other Name: AZD6738
Experimental: Arm O. Futibatinib (TAS-120)
Futibatinib tablets orally on a continuous dosing QD per 28 day cycle
 Drug: Futibatinib
Other Name: Tas-120
Experimental: Arm P. Capmatinib (INC280) + Everolimus
Capmatinib tablets orally on a continuous dosing BID per 28 day cycle. Everolimus dispersible tablets orally QD on a continuous dosing per 28 day cycle.
 Drug: Everolimus
Other Name: Afinitor

Drug: Capmatinib
Other Names:
  • Tabrecta
  • INC280


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Recommended phase II dose (RP2D) [ Time Frame: During the first cycle ]
    Defined as the adult recommended dose (adjusted for weight or BSA) if toxicity and/or PK profiling are similar in children and in adults, or a higher dose, providing it is below or equal to the maximum tolerated dose (MTD)

  2. Maximum Tolerated Dose (MTD) [ Time Frame: During the first cycle ]
    The MTD will be defined as the dose associated with or closest to 25% of Dose Limiting Toxicities (DLTs)

  3. Objective Response Rate (ORR) [ Time Frame: During treatment period ]

    Defined as the proportion of participants who achieved a confirmed complete response (CR) or partial response (PR) assessed by investigators.

    In patients with leukemia, ORR is defined as the percentage of patients attaining CR, CRi or CRp.



Secondary Outcome Measures :
  1. Pharmacokinetics (PK) [ Time Frame: Depending on the treatment arm ]
    To characterize single or multiple-dose PK of the agent(s)

  2. Progression Free Survival (PFS) [ Time Frame: From treatment initiation until the date of first documented progression or death ]
    Defined as the time from treatment initiation until the date of first documented progression (clinically or radiologically) or death from any cause. Patients alive and free of progression at the cut-off date will be censored at the last assessment date.

  3. Evaluation of duration of response (DoR) [ Time Frame: Between the first document response and the time of first documented progression ]
    Defined as the time period between the first documented response (complete response (CR) or partial response (PR)) and the time of progression, according to RECIST v1.1, RANO criteria for patients with HGG, INRC criteria for patients with NB, etc.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must be diagnosed with a haematologic or solid tumor malignancy that has progressed despite standard therapy, or for which no effective standard therapy exists.
  2. Age < 18 years at inclusion; patients 18 years and older may be included after discussion with the sponsor if they have a pediatric recurrent/refractory malignancy.
  3. Patient must have had advanced molecular profiling (i.e. WES/WGS +/- RNAseq) of their recurrent or refractory tumor i.e. at the time of disease progression/relapse; exceptionally patients with advanced molecular profiling at diagnosis may be allowed.
  4. Evaluable or measurable disease as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1, RANO criteria for patients with HGG, INRC criteria for patients with NB, Leukemia criteria, etc.).
  5. Patients with relapsed or refractory leukemia are eligible for this study.
  6. Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  7. Life expectancy ≥ 3 months

  8. Adequate organ function:

    Hematologic criteria (Leukemia patients are excluded from hematological criteria):

    • Peripheral absolute neutrophil count (ANC) ≥ 1000/μL(unsupported)
    • Platelet count ≥ 100,000/μL (unsupported)
    • Hemoglobin ≥ 8.0 g/dL (transfusion is allowed)

    Cardiac function:

    • Shortening fraction (SF) >29% (>35% for children < 3 years) and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).
    • Absence of QTc prolongation (QTc > 450 msec on baseline ECG, using the Fridericia correction [QTcF formula]) or other clinically significant ventricular or atrial arrhythmia.

    Renal and hepatic function:

    • Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age
    • Total bilirubin ≤ 1.5 x ULN
    • Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 2,5 x ULN; aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase/SGOT ≤ 2,5 x ULN except in patients with documented tumor involvement of the liver who must have AST/SGOT and ALT/SGPT ≤ 5 x ULN.
  9. Able to comply with scheduled follow-up and with management of toxicity.
  10. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of treatment. Sexually active women of childbearing potential must agree to use acceptable and appropriate contraception during the study and for at least 6 months after the last study treatment administration. Sexually active males patients must agree to use condom during the study and for at least 6 months (7 months for arm J) after the last study treatment administration. Acceptable contraception are defined in CTFG Guidelines "Recommendations related to contraception and pregnancy testing in clinical trials"
  11. For all oral medications patients must be able to comfortably swallow capsules (except for those for which an oral solution is available); nasogastric or gastrostomy feeding tube administration is allowed only if indicated.
  12. Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
  13. Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.

Exclusion Criteria:

  1. Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or require increasing doses of corticosteroids or local CNS-directed therapy to control their CNS disease. Patients on stable doses of corticosteroids for at least 7 days prior to receiving study drug may be included.
  2. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
  3. Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality, unstable ischemia,congestive heart failure within 12 months of screening)
  4. Active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
  5. Presence of any ≥ CTCAE grade 2 treatment-related toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.
  6. Systemic anticancer therapy within 21 days of the first study dose or 5 times its half-life, whichever is less.
  7. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8 weeks of the first study drug dose
  8. Allogeneic stem cell transplant within 3 months prior to the first study drug dose. Patients receiving any agent to treat or prevent graft-versus host disease (GVHD) post bone marrow transplant are not eligible for this trial.
  9. Radiotherapy (non-palliative) within 21 days prior to the first dose of drug (or within 6 weeks for therapeutic doses of MIBG or craniospinal irradiation).
  10. Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
  11. Currently taking medications with a known risk of prolonging the QT interval or inducing Torsades de Pointes (Refer to Appendix 8).
  12. Currently taking medications that are mainly metabolized by CYP3A4/5, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 and have a low therapeutic index that cannot be discontinued at least 7 days or 5 x reported elimination half-life prior to start of treatment with any of the investigational drugs and for the duration of the study (Refer to Appendix 9).
  13. Known hypersensitivity to any study drug or component of the formulation.
  14. Pregnant or nursing (lactating) females.
  15. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study drug.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02813135


Contacts
Layout table for location contacts
Contact: Birgit Geoerger, MD +33 (0)1 42 11 46 61 birgit.geoerger@gustaveroussy.fr
Contact: Jonathan Rubino, MS +33 (0)1 42 11 58 87 jonathan.rubino@gustaveroussy.fr

Locations
Layout table for location information
Denmark
Rigshospitalet Not yet recruiting
Copenhagen, Denmark, 2100
Contact: Karsten Nyson, MD    +45 35 45 08 09    karsten.nysom@regionh.dk   
France
Gustave Roussy Recruiting
Villejuif, Val De Marne, France, 94805
Contact: Birgit Geoerger, MD    +33 (0)1 42 11 46 61    birgit.geoerger@gustaveroussy.fr   
Contact: Jonathan Rubino, MS    +33 (0)1 42 11 58 87    jonathan.rubino@gustaveroussy.fr   
Principal Investigator: Birgit Geoerger, MD         
Germany
University Children's Hospitalermany Not yet recruiting
Heidelberg, Germany
Contact: Olaf Witt, MD    +49 6221 56 4555    O.Witt@Dkfz-Heidelberg.de   
Italy
Fondazione IRCCS Istituto Nazionale dei Tumori Recruiting
Milan, Italy
Contact: Michela Casanova, MD    +39 02 23 90 25 94    Michela.Casanova@istitutotumori.mi.it   
Netherlands
Erasmus MC, Sophia Children's Hospital Active, not recruiting
Rotterdam, Netherlands
Spain
Unidad de Oncología Pediátrica Hospital Niño Jesús Recruiting
Madrid, Spain, 28009
Contact: Alba Rubio, MD    +43 915 03 59 00    franciscojose.bautista@salud.madrid.org   
United Kingdom
Pediatric and Adolescent Oncology The Royal Marsden Hospital Recruiting
Sutton, United Kingdom
Contact: Lynley Marshall, MD    +44 208 661 3678    Lynley.Marshall@icr.ac.uk   
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France
Investigators
Layout table for investigator information
Study Chair: Birgit Geoerger, MD Gustave Roussy, Cancer Campus, Grand Paris
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT02813135    
Other Study ID Numbers: 2016-000133-40
2016/2396 ( Other Identifier: CSET Number )
First Posted: June 24, 2016    Key Record Dates
Last Update Posted: May 30, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gustave Roussy, Cancer Campus, Grand Paris:
Children
Adolescents
Young adults
Recurrent malignancies
Refractory malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Congenital Abnormalities
Cytarabine
Dexamethasone
Cyclophosphamide
Temozolomide
Carboplatin
Nivolumab
Irinotecan
Everolimus
Topotecan
Olaparib
Futibatinib
Adavosertib
Immunosuppressive Agents
Immunologic Factors
 Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists